We are live on ! Find out more
RA

Royce & Associates Portfolio holdings

AUM $10.1B
1-Year Est. Return 42.88%
This Fund
S&P 500
This Quarter Est. Return
+4.87%
1 Year Est. Return
+42.88%
3 Year Est. Return
+92.52%
5 Year Est. Return
+113.84%
10 Year Est. Return
+608.05%
AUM
$14.6B
AUM Growth
-$325M
Cap. Flow
-$723M
Cap. Flow %
-4.97%
Top 10 Hldgs %
7.37%
Holding
1,080
New
68
Increased
314
Reduced
422
Closed
79

Top Sells

Rank Stock Value
1
IMXI icon
International Money Express
IMXI
+$42M
2
OLN icon
Olin
OLN
+$40.2M
3
BC icon
Brunswick
BC
+$36.7M
4
AA icon
Alcoa
AA
+$33.9M
5
USCR
U S Concrete, Inc.
USCR
+$31.9M

Sector Composition

Rank Sector Weight
1 Industrials 24.2%
2 Technology 20.04%
3 Financials 15.03%
4 Consumer Discretionary 13.3%
5 Healthcare 8.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BELFA icon
851
Bel Fuse Inc Class A
BELFA
$2.88B
$970K 0.01%
67,705
BWIN
852
Baldwin Insurance Group
BWIN
$2.75B
$959K 0.01%
+36,000
New +$976K
SMHI icon
853
SEACOR Marine Holdings
SMHI
$209M
$957K 0.01%
216,957
LVOX
854
DELISTED
LiveVox Holding, Inc. Class A Common Stock
LVOX
$951K 0.01%
+113,929
New +$1.12M
ABM icon
855
ABM Industries
ABM
$2.89B
$926K 0.01%
20,890
+3,674
+21% +$184K
AMCX icon
856
AMC Global Media
AMCX
$450M
$918K 0.01%
13,744
+2,573
+23% +$142K
KRMD icon
857
KORU Medical Systems
KRMD
$187M
$895K 0.01%
193,300
+91,100
+89% +$358K
FBP icon
858
First Bancorp
FBP
$4.41B
$894K 0.01%
75,018
-11,024
-13% -$136K
HIMS.WS
859
DELISTED
Hims & Hers Health, Inc. Warrants, each whole warrant exercisable for one Class A Common Stock at an
HIMS.WS
$893K 0.01%
266,666
RMBS icon
860
Rambus
RMBS
$8.98B
$877K 0.01%
36,981
-8,985
-20% -$181K
GPRK icon
861
GeoPark
GPRK
$609M
$876K 0.01%
69,218
HI
862
DELISTED
Hillenbrand
HI
$876K 0.01%
19,882
-1,505
-7% -$70.2K
GIII icon
863
G-III Apparel Group
GIII
$1.54B
$870K 0.01%
26,490
-505
-2% -$16.3K
SHOO icon
864
Steven Madden
SHOO
$3.17B
$868K 0.01%
19,843
-3,080
-13% -$127K
ABCB icon
865
Ameris Bancorp
ABCB
$5.89B
$858K 0.01%
16,944
+1,670
+11% +$89.7K
TBPH icon
866
Theravance Biopharma
TBPH
$873M
$857K 0.01%
59,009
MODN
867
DELISTED
MODEL N, INC.
MODN
$857K 0.01%
25,000
-25,000
-50% -$917K
LFCR icon
868
Lifecore Biomedical
LFCR
$162M
$851K 0.01%
75,610
AEYE icon
869
AudioEye
AEYE
$71.5M
$839K 0.01%
50,000
WNS
870
DELISTED
WNS Holdings
WNS
$839K 0.01%
10,500
-4,700
-31% -$349K
WTFC icon
871
Wintrust Financial
WTFC
$10.7B
$832K 0.01%
11,000
OSG
872
Octave Specialty Group
OSG
$257M
$830K 0.01%
53,000
SUNL
873
DELISTED
Sunlight Financial Holdings, Inc.
SUNL
$807K 0.01%
+4,038
New +$807K
MGLN
874
DELISTED
Magellan Health Services, Inc.
MGLN
$779K 0.01%
8,265
-1,859
-18% -$175K
HOLI
875
DELISTED
Hollsys Automation Technologies INTERNATIONAL, LTD. COMMON (British Virgin Island)
HOLI
$773K 0.01%
51,900

Similar funds

Royce & Associates's Q2 2021 Portfolio in Review

As of Q2 2021, Royce & Associates held 1,080 positions worth $14.6B, down 2.2% from $14.9B the previous quarter. Its ten largest holdings account for 7.4% of the portfolio.

Royce & Associates withdrew a net $723M in Q2 2021, closing 79 positions and reducing 422 holdings. Its most notable exit was Olin, an estimated $40.2M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 24% of assets, up from 24% a quarter earlier, followed by Technology and Financials.

Against the trend, Royce & Associates opened a new position in Organon & Co worth $16.5M.

  • Royce & Associates's largest Q2 2021 buy was Organon & Co: 546,803 shares worth $16.5M.
  • Royce & Associates added most to Vontier in Q2 2021, an estimated $50.7M increase.
  • Royce & Associates's biggest Q2 2021 reduction was International Money Express, cutting an estimated $42M.
  • Royce & Associates fully exited Olin in Q2 2021, selling an estimated $40.2M.
  • Royce & Associates's ten largest holdings make up 7.4% of its $14.6B portfolio in Q2 2021.
  • Royce & Associates opened 68 new positions and closed 79 in Q2 2021.
  • Royce & Associates's portfolio value fell 2.2% quarter-over-quarter to $14.6B.

Based on Royce & Associates's 13F filing for Q2 2021, filed 6 Aug 2021.